Edition:
United Kingdom

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

8.20USD
13 Dec 2017
Change (% chg)

$0.15 (+1.86%)
Prev Close
$8.05
Open
$8.10
Day's High
$8.30
Day's Low
$8.05
Volume
214,735
Avg. Vol
260,877
52-wk High
$15.35
52-wk Low
$4.10

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $846.68
Shares Outstanding(Mil.): 68.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

26 Oct 2017

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

16 Oct 2017

BRIEF-TG Therapeutics announces completion of target enrollment

* TG Therapeutics announces completion of target enrollment in the unity-CLL phase 3 trial

05 Sep 2017

BRIEF-TG Therapeutics announces successful outcome from first pre-planned interim analysis

* TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial

10 Aug 2017

BRIEF-TG Therapeutics Q2 loss per share ‍$0.45​

* Tg therapeutics Inc provides business update and reports second quarter 2017 financial results

09 Aug 2017

BRIEF-TG therapeutics provides FDA update on multiple sclerosis study

* Announces special protocol assessment (spa) agreement with the FDA for a Phase 3 program of TG-1101 (ublituximab) for patients with multiple sclerosis (MS)

01 Aug 2017

BRIEF-TG Therapeutics provides additional data from early-stage cancer drug study

* Tg therapeutics - triple combination of tg-1101, tgr-1202 and bendamustine was generally well-tolerated with only gr 3/4 event >10% being neutropenia

15 Jun 2017

BRIEF-TG Therapeutics says follow-up data for combination of TGR-1202 plus Ibrutinib

* TG Therapeutics, Inc. Announces follow-up data for combination of TGR-1202 (umbralisib) plus ibrutinib in patients with relapsed or refractory cll and mcl at the 14th international conference on malignant lymphoma

14 Jun 2017

Competitors

Earnings vs. Estimates